Rates of adverse and serious adverse events in children with cystic fibrosis

Cystic fibrosis (CF) is an autosomal recessive disease characterized by chronic sinopulmonary symptoms and chronic gastrointestinal symptoms that begins in infancy [1]. There have been tremendous advances in CF care and drugs targeting aspects of the disease, with new cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies offering the promise to significantly alter the trajectory of CF lung disease for a majority of patients. Children with CF are increasingly being included in clinical trials.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original article Source Type: research